Earlier Monday, the U.S. FDA approved Bausch + Lomb's (BlCO) eye surgery product, the Teneo Excimer Laser Platform, to conduct a surgical procedure called keratomileusis (LASIK).

Bausch + Lomb said it authorized management and advisers to explore a potential sale of the eye health company after shares dropped over reports of faltering deal talks with a group of private ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of ... intraocular lenses, and eye surgery products, and made revenues of $4.15 billion last year.

Papa took over as the new CEO of Bausch & Lomb, and oversaw the $2.5bn acquisition of the dry eye disease therapy XIIDRA and other ophthalmology assets from Swiss Pharma giant Novartis AG (NVS ...

Elios Vision former chairman and CEO Elliot Friedman said: “Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eye care professionals and help ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an ...

Learn more about whether Bausch + Lomb Corporation or Omnicell, Inc. is a better investment based on AAII's A+ Investor ...

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic competition in ...

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic ...